ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 363.7 | 370.4 | 338.7 |
| Other income | 3.9 | 4.0 | 4.0 |
| Total income | 367.6 | 374.4 | 342.8 |
| Profit before exceptional items & tax | 97.3 | 133.2 | 88.8 |
| Exceptional items | 31.8 | 0.0 | 0.0 |
| Profit before tax | 129.1 | 133.2 | 88.8 |
| Net profit | 96.2 | 94.6 | 66.2 |
| Operating margin | 35.1% | 35.6% | 25.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +45.30% |
|---|---|
| Net profit, quarter on quarter | +1.70% |
| Revenue, year on year | +7.40% |
| Operating profit, year on year | +10.10% |
| Operating profit, quarter on quarter | -27.70% |
NSE results filing, NSE: PGHL. Figures extracted from the filing.
Procter & Gamble Health Ltd: key numbers
- Share price
- ₹5,790.00
- Market cap
- ₹9,611 Cr
- Revenue (annual)
- ₹1,408 Cr
- Net profit (annual)
- ₹326.9 Cr
- P/E (TTM)
- 25.3×Sector 43.8×
- Promoter holding
- 51.82%+0.00% QoQ
- FII holding
- 6.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Procter & Gamble Health Ltd
All →Procter & Gamble Health Results Update
P&G Health's Q2 sales grew 18% to ₹376 crore and PAT rose 26% to ₹112 crore. Growth driven by brand strength and retail execution.
Procter & Gamble Health Q2 FY27 Results: Net Profit ₹111.5 Cr, Up 26.0% YoY
Procter & Gamble Health Ltd reported revenue from operations of ₹382.5 Cr (+17.7% YoY) and net profit of ₹111.5 Cr (+26.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹111.5 Cr · +26.0% YoY
Procter & Gamble Health Board Meeting Date
Procter & Gamble Health Limited will hold a board meeting on November 2, 2026, to consider and approve the unaudited financial results for the quarter ending September 30, 2026.
Procter & Gamble Health Other Announcement
Procter & Gamble Health informed shareholders about an extended SEBI-mandated special window for re-lodging rejected physical share transfer requests until February 4, 2027.
Procter & Gamble Health Management Change
Procter & Gamble Health shareholders approved the re-appointment of Mr. S. Madhavan as an Independent Director for a five-year term starting November 15, 2026.
- Execution
- 5 years
Procter & Gamble Health Annual General Meeting
Procter & Gamble Health held its 59th Annual General Meeting on September 3, 2026, where shareholders discussed financial results and directorial appointments.